| Year |
Citation |
Score |
| 2014 |
Godbole AM, Ramalingam S, Ramamurthy VP, Khandelwal A, Bruno RD, Upreti VV, Gediya LK, Purushottamachar P, Mbatia HW, Addya S, Ambulos N, Njar VC. VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. European Journal of Pharmacology. 734: 98-104. PMID 24726842 DOI: 10.1016/J.Ejphar.2014.04.004 |
0.674 |
|
| 2008 |
Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics. 7: 2348-57. PMID 18723482 DOI: 10.1158/1535-7163.MCT-08-0230 |
0.677 |
|
| 2008 |
Gediya LK, Khandelwal A, Patel J, Belosay A, Sabnis G, Mehta J, Purushottamachar P, Njar VC. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. Journal of Medicinal Chemistry. 51: 3895-904. PMID 18543902 DOI: 10.1021/Jm8001839 |
0.749 |
|
| 2008 |
Khandelwal A, Gediya L, Njar V. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. British Journal of Cancer. 98: 1234-43. PMID 18349838 DOI: 10.1038/Sj.Bjc.6604295 |
0.702 |
|
| 2008 |
Purushottamachar P, Khandelwal A, Vasaitis TS, Bruno RD, Gediya LK, Njar VC. Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorganic & Medicinal Chemistry. 16: 3519-29. PMID 18316193 DOI: 10.1016/J.Bmc.2008.02.031 |
0.762 |
|
| 2008 |
Gediya LK, Belosay A, Khandelwal A, Purushottamachar P, Njar VC. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorganic & Medicinal Chemistry. 16: 3352-60. PMID 18166465 DOI: 10.1016/J.Bmc.2007.12.007 |
0.721 |
|
| 2008 |
Gediya L, Purushottamachar P, Khandelwal A, Mehta J, Godbole A, Njar V. 27 INVITED Novel atypical retinoic acid metabolism blocking agents (RAMBAs)/ CYP26 inhibitors for breast cancer therapy European Journal of Cancer Supplements. 6: 12. DOI: 10.1016/S1359-6349(08)71959-1 |
0.767 |
|
| 2007 |
Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. British Journal of Cancer. 96: 1204-15. PMID 17387344 DOI: 10.1038/Sj.Bjc.6603705 |
0.773 |
|
| 2007 |
Purushottamachar P, Khandelwal A, Chopra P, Maheshwari N, Gediya LK, Vasaitis TS, Bruno RD, Clement OO, Njar VC. First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorganic & Medicinal Chemistry. 15: 3413-21. PMID 17383188 DOI: 10.1016/J.Bmc.2007.03.019 |
0.752 |
|
| 2007 |
Patel JB, Khandelwal A, Chopra P, Handratta VD, Njar VC. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemotherapy and Pharmacology. 60: 899-905. PMID 17345084 DOI: 10.1007/S00280-007-0438-3 |
0.784 |
|
| 2006 |
Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorganic & Medicinal Chemistry. 14: 4323-40. PMID 16530416 DOI: 10.1016/J.Bmc.2006.02.041 |
0.732 |
|
| 2006 |
Njar VCO, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J. Retinoic Acid Metabolism Blocking Agents (RAMBAs) for Treatment of Cancer and Dermatological Diseases Cheminform. 37. DOI: 10.1002/CHIN.200637236 |
0.623 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5845-9. PMID 22962441 DOI: 10.1158/1078-0432.Ccr-12-1803 |
0.241 |
|
| 2021 |
Reynolds KL, Arora S, Elayavilli RK, Louv WC, Schaller TH, Khandelwal A, Rothenberg M, Khozin S, Guidon AC, Dougan M, Zubiri L, Petrillo L, Sise ME, Villani AC, Johnson DB, et al. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. Journal For Immunotherapy of Cancer. 9. PMID 34215691 DOI: 10.1136/jitc-2021-002896 |
0.196 |
|
| 2022 |
Agarwal A, Khandelwal A, Pal K, Khare NK, Jadhav V, Gurjar M, Punatar S, Gokarn A, Bonda A, Nayak L, Kannan S, Gota V, Khattry N, Mittra I. A novel pro-oxidant combination of resveratrol and copper reduces transplant related toxicities in patients receiving high dose melphalan for multiple myeloma (RESCU 001). Plos One. 17: e0262212. PMID 35120140 DOI: 10.1371/journal.pone.0262212 |
0.165 |
|
| 2018 |
Khandelwal A, Sehrawat A, S. Sindhu S. Growth Suppression of Chenopodium album Weed and Growth Promotion Effect on Wheat (Triticum aestivum L.) by Inoculation of δ-Aminolevulinic Acid Producing Rhizobacteria International Journal of Current Microbiology and Applied Sciences. 7: 1958-1971. DOI: 10.20546/IJCMAS.2018.702.235 |
0.133 |
|
| 2011 |
Casak SJ, Lemery SJ, Shen YL, Rothmann MD, Khandelwal A, Zhao H, Davis G, Jarral V, Keegan P, Pazdur R. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. The Oncologist. 16: 97-104. PMID 21212432 DOI: 10.1634/theoncologist.2010-0306 |
0.096 |
|
| 2020 |
Singhavi HR, Khare N, Singh A, Khandelwal A, Kannan S, Patil A, Mittra I, Chaturvedi P. Impact of pre-operative serum C-reactive protein and cell-free chromatin levels on tumor aggressiveness and survival outcome in oral cavity squamous cell carcinoma. Oral Oncology. 105078. PMID 33183996 DOI: 10.1016/j.oraloncology.2020.105078 |
0.092 |
|
| Hide low-probability matches. |